drugset
drugset / Trial / NCT05148312

Single-dose AQ001S PK Study in Healthy Volunteers

NCT05148312 ↗

Phase 1 Completed 29 enrolled Aquilon Pharmaceuticals S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers.

Timeline

Start
2021-11-12
Primary completion
2021-12-24
Completion
2022-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 0.125 mg Inhaled
Subject Budesonide Small molecule 0.25 mg Inhaled
Subject Budesonide Small molecule 0.5 mg Inhaled
Subject Budesonide Small molecule 1 mg Inhaled

Indications

No indication recorded.